- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04684563
huCART19-IL18 chez les patients atteints de LNH/LLC
Essai de phase I des cellules huCART19-IL18 chez des patients atteints de lymphome non hodgkinien (LNH) CD19+ récidivant ou réfractaire et de leucémie lymphoïde chronique (LLC)
The purpose of this study is to evaluate the safety and feasibility of huCART19-IL18 cells in patients with relapsed or refractory CD19+ cancers.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a Phase I study to assess the safety, tolerability, manufacturing feasibility, pharmacokinetics, and preliminary efficacy of huCART19-IL18 cells in patients with CD19+ cancers. The study will take place in two parts: an initial Dose-Finding Phase and an Expansion Phase. In the dose-finding phase, the maximum tolerated dose will be determined using a Bayesian Optimal Interval (BOIN) design within each of the following disease-specific cohorts:
- Cohort A: Non-Hodgkin Lymphoma (Active, Not Recruiting)
- Cohort B: Chronic Lymphocytic Leukemia (Active, Not Recruiting)
- Cohort C: Acute Lymphoblastic Leukemia (Active, Not Recruiting)
- Cohort D (Expansion Phase): Non Hodgkin Lymphoma and Acute Lymphoblastic Leukemia (Active, Not Recruiting) will evaluate changes to cell activation method in the huCART19-IL18 manufacturing process using the recommended dose for expansion (RDE) arising out of the dose-finding phase.
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- University of Pennsylvania
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Signed informed consent form
-
Documentation of CD19 expression on malignant cells by flow cytometry/IHC from a CLIA certified laboratory
NHL Patients: Within 6 months of physician-investigator confirmation of eligibility as long as there has been no intervening CD19 directed therapy since expression confirmed. Results outside of this window may be used, if there is no accessible tumor site and the subject did not receive intervening CD19 directed therapy since CD19 expression was confirmed.
CLL and ALL Patients: At time of most recent relapse. If the subject has subsequently received CD19-directed therapy since this result was obtained, repeating testing must be performed to determine eligibility.
-
Patients with relapsed disease after prior allogeneic SCT must meet the following criteria:
a. Have no active GVHD and require no immunosuppression b. Are more than 6 months from transplant at the time of physician-investigator confirmation of eligibility
-
Adequate organ function defined as:
a. Creatinine ≤ 1.6 mg/dl b. ALT/AST ≤ 3x upper limit of normal range c. Direct bilirubin ≤ 2.0 mg/dl, unless the subject has Gilbert's syndrome (≤3.0 mg/dl) d. Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygen > 92% on room air e. Left Ventricle Ejection Fraction (LVEF) ≥ 40% confirmed by ECHO/MUGA
-
Evidence of active disease within 12 weeks of physician-investigator confirmation of eligibility. .
-
Male or female age ≥ 18 years.
-
ECOG Performance Status that is either 0 or 1.
-
Subjects of reproductive potential must agree to use acceptable birth control methods.
-
Disease-specific criteria:
NHL Patients (Cohorts A and D):
i. Patients with any of the following diagnoses: Diffuse Large B-cell Lymphoma not otherwise specified (DLBCL NOS), germinal center or activated B-cell types;Primary Cutaneous DLBCL; Primary Mediastinal (thymic) Large B-cell Lymphoma; ALK+ Anaplastic Large B-cell Lymphoma; High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 rearrangements (i.e., "Double or Triple Hit"); High-grade B-cell Lymphoma, NOS; T-cell Rich B-cell Lymphoma; Transformed Follicular Lymphoma; or any aggressive B-cell lymphoma arising from indolent lymphoma.
1. Patients must have either relapsed after, or be ineligible for, prior CAR T cell therapy, and meet one of the following criteria:
-
Relapsed/refractory disease after at least 2 prior lines of appropriate therapy; OR
-
Relapsed/refractory disease after autologous SCT; OR
-
Relapsed/refractory disease after allogeneic SCT. ii. Follicular lymphoma
- Patients must have either relapsed after, or be ineligible for, prior commercial CAR T cell therapy; AND
- Received at least 2 prior lines of appropriate therapy (not including single agent monoclonal antibody therapy) and progressed within 2 years after second or higher line of therapy.
iii. Mantle cell lymphoma
-
Patients must have either failed standard of care CAR T cell therapy (e.g., Tecartus™, etc) or other investigational CAR T cell product, OR be ineligible for standard of care Tecartus™; and
-
Patients must also meet one of the following criteria:
- Relapsed/refractory disease after at least 2 prior lines of appropriate therapy, including a BTK inhibitor. Single-agent monoclonal antibody therapy does not count towards prior lines of therapy; OR
- Relapsed/refractory disease after prior autologous SCT; OR
- Relapsed/refractory disease after prior allogeneic SCT.
CLL Patients (Cohort B):
i. Chronic Lymphocytic Leukemia
- Patients with relapsed/refractory disease after at least 2 prior lines of appropriate therapy; AND
- Patients must have previously received or be intolerant to an approved BTK inhibitor and venetoclax, unless a BTK inhibitor or venetoclax is contraindicated.
ii. Large cell transformation of CLL (Richter's Transformation)
1. Patients must be primary refractory or received at least 1 prior line of treatment for Richter's Transformation.
c. ALL Patients (Cohorts C and D): i. Patients with b-cell acute lymphoblastic leukemia. Note: Chronic myeloid leukemia (CML) lymphoid blast crisis is considered a sub-type of relapsed B-ALL, thus will be encompassed in our definition of B-ALL throughout; AND ii. Patients with 2nd or greater relapse or refractory disease as defined by one of the following criteria:
-
Recurrent disease in the blood or bone marrow identified morphologically, by IHC or flow; OR
-
Isolated CNS disease. Note: Patients with prior/current history of CNS3 disease will only be eligible for treatment if the CNS disease is responsive to therapy; OR
-
Recurrent extramedullary disease at other (non-CNS) sites if disease response can be assessed radiographically. Note: Patients with recurrent extramedullary disease do not need to have detectable blood or bone marrow involvement; OR
-
Any relapse after allogeneic SCT; OR
-
Patients with refractory disease as defined by one of the following:
- Failure to achieve remission (<5% bone marrow blasts or ongoing extramedullary or CNS disease) after 2 cycles of induction chemotherapy; OR
- Patients that achieve remission but remain MRD+ after ≥2 cycles of induction chemotherapy.
Exclusion Criteria:
-
Active hepatitis B, active hepatitis C, or other active, uncontrolled infection.
-
Class III/IV cardiovascular disability according to the New York Heart Association Classification.
-
Clinically apparent arrhythmia or arrhythmias that are not stable on medical management within two weeks of physician-investigator confirmation of eligibility.
-
Active acute or chronic GVHD requiring systemic therapy.
-
Dependence on systemic steroids or immunosuppressant medications. For additional details regarding use of steroid and immunosuppressant medications.
-
RETIRED WITH PROTOCOL AMENDMENT V7
-
Receipt of prior huCART19 therapy.
-
CNS disease as defined by disease-cohort as follows:
- NHL/CLL Patients: Active CNS disease. Note: Patients with a history of CNS involvement that was successfully treated are eligible. A CNS evaluation is only required for eligibility if a subject is experiencing signs/symptoms of CNS involvement.
- ALL Patients: CNS3 disease that is progressive on therapy, or with CNS parenchymal lesions that might increase the risk of CNS toxicity.
-
Pregnant or nursing (lactating) women.
-
Patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system, and unrelated to their cancer or previous cancer treatment.
-
Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to ≥ 10mg of prednisone. Patients with autoimmune neurologic diseases (such as MS) will be excluded.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Cohort A: NHL Dose Level 1a (DL1a)
3x10^6 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push |
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18) |
|
Expérimental: Cohort A: NHL Dose Level -1 (DL-1)
7x10^5 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push; This dose level will only be explored if at least one DLT is observed at Dose Level 1a. |
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18) |
|
Expérimental: Cohort A: NHL Dose Level 1b (DL1b)
3x10^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push |
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18) |
|
Expérimental: Cohort A: NHL Dose Level 2 (DL2)
7x10^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push |
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18) |
|
Expérimental: Cohort A: NHL Dose Level 3 (DL3)
3x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push |
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18) |
|
Expérimental: Cohort A: NHL Dose Level 4 (DL4)
7x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push |
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18) |
|
Expérimental: Cohort A: NHL Dose Level 5 (DL5)
3x10^8 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push |
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18) |
|
Expérimental: Cohort B: CLL Dose Level 1b (DL1b)
3x10^6 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push; This dose level will only be explored if at least one DLT is observed at Dose Level 2. |
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18) |
|
Expérimental: Cohort B: CLL Dose Level 2 (DL2)
7x10^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push |
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18) |
|
Expérimental: Cohort B: CLL Dose Level 3 (DL3)
3x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push |
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18) |
|
Expérimental: Cohort B: CLL Dose Level 4 (DL4)
7x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push |
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18) |
|
Expérimental: Cohort B: CLL Dose Level 5 (DL5)
3x10^8 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push |
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18) |
|
Expérimental: Cohort C: ALL Dose Level 1b (DL1b)
3x10^6 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push; This dose level will only be explored if at least one DLT is observed at Dose Level 2. |
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18) |
|
Expérimental: Cohort C: ALL Dose Level 2 (DL2)
7x10^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push |
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18) |
|
Expérimental: Cohort C: ALL Dose Level 3 (DL3)
3x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push |
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18) |
|
Expérimental: Cohort C: ALL Dose Level 4 (DL4)
7x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push |
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18) |
|
Expérimental: Cohort C: ALL Dose Level 5 (DL5)
3x10^8 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push |
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18) |
|
Expérimental: Cohort D: NHL
7x10^6 huCART19-IL18 as a single intravenous (IV) infusion or slow IV push |
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18) |
|
Expérimental: Cohort D: ALL
7x10^6 huCART19-IL18 as a single intravenous (IV) infusion or slow IV push |
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18) |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0
Délai: Up to 15 years post-huCART19-IL18 infusion
|
Cohorts A-C: Type, frequency and severity of adverse events as assessed by CTCAE V5.0. Each disease-specific cohort will be analyzed separately. |
Up to 15 years post-huCART19-IL18 infusion
|
|
Occurrence of dose-limiting toxicities (DLTs)
Délai: 28 days post-huCART19-IL18 infusion
|
Cohorts A-C: Unacceptable toxicity as defined by the protocol. DLTs will be evaluated separately by each disease-specific cohort. |
28 days post-huCART19-IL18 infusion
|
|
Determination of Maximum Tolerated Dose (MTD)
Délai: 28 days post-huCART19-IL18 infusion
|
Cohorts A-C: Selected based on an isotonic regression model. The MTD will be established separately by disease-specific cohort. |
28 days post-huCART19-IL18 infusion
|
|
Determination of a recommended dose for expansion (RDE)
Délai: 3 months post-huCART19-IL18 infusion
|
Cohorts A-C: Evaluated by Cohort/dose level using a multi-criteria decision analysis. |
3 months post-huCART19-IL18 infusion
|
|
Proportion of manufactured products that meet the product release criteria
Délai: 3 months
|
Cohort D: Calculated based on the proportion of subjects with huCART19-IL18 products that fail to meet the product release criteria, out of the number of subjects in whom manufacturing was attempted. |
3 months
|
|
Proportion of manufactured products that meet the assigned dose
Délai: 3 months
|
Cohort D: Calculated based on the proportion of subjects with huCART19-IL18 products that fail to meet the assigned dose, out of the number of subjects in whom manufacturing was attempted. |
3 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of manufacturing products that meet the product release criteria
Délai: 3 months
|
Cohorts A-C: Calculated based on the proportion of subjects with huCART19-IL18 products that fail to meet the product release criteria, out of the number of subjects in whom manufacturing was attempted. Will be evaluated separately by each disease-specific cohort. |
3 months
|
|
Proportion of manufactured products that meet the assigned dose
Délai: 3 months
|
Cohorts A-C: Calculated based on the proportion of subjects with huCART19-IL18 products that fail to meet the assigned dose, out of the number of subjects in whom manufacturing was attempted. Will be evaluated separately by each disease-specific cohort. |
3 months
|
|
Incidence of Treatment-Emergent Adverse Events
Délai: 3 months
|
Cohort D: Type, frequency and severity of adverse events as assessed by CTCAE V5.0. |
3 months
|
|
Overall Response Rate (ORR)
Délai: 3 months post-huCART19-IL18 infusion
|
NHL and CLL Patients: The proportion of subjects with CR or PR at Month 3 as compared to baseline. |
3 months post-huCART19-IL18 infusion
|
|
Overall Response Rate (ORR)
Délai: 1 month post-huCART19-IL18 infusion
|
ALL Patients: The proportion of subjects with CR/CRi/CR(MRD-) at Day 28 as compared to baseline |
1 month post-huCART19-IL18 infusion
|
|
Best Overall Response (BOR)
Délai: 12 months post-huCART19-IL18 infusion
|
NHL and CLL Patients: The proportion of subjects with a best overall disease response of CR or PR between Month 3 and Month 12, and prior to the start of new anticancer therapy. |
12 months post-huCART19-IL18 infusion
|
|
Best Overall Response (BOR)
Délai: 6 months post-huCART19-IL18 infusion
|
ALL Patients: The proportion of subjects with CR/CRi/CR(MRD-) by Month 6, and prior to the start of new anticancer therapy. |
6 months post-huCART19-IL18 infusion
|
|
Duration of Response (DOR)
Délai: Up to 15 years post-huCART19-IL18 infusion
|
NHL and CLL Patients: Duration from the date when CR/PR is first met at/after Month 3, to the date of relapse, death, or receipt of new anticancer therapy. |
Up to 15 years post-huCART19-IL18 infusion
|
|
Duration of Remission (DOR)
Délai: Up to 15 years post-huCART19-IL18 infusion
|
ALL Patients: Duration from the date when CR/CRi/CR(MRD-) is first met to the date of relapse, death or receipt of new anticancer therapy |
Up to 15 years post-huCART19-IL18 infusion
|
|
Progression-Free Survival (PFS)
Délai: 12 monthsUp to 15 years post-huCART19-IL18 infusion
|
NHL and CLL Patients: Duration of time from the huCART19-IL18 infusion to the date of the disease progression/relapse, death or receipt of new anticancer therapy |
12 monthsUp to 15 years post-huCART19-IL18 infusion
|
|
Event-Free Survival (EFS)
Délai: Up to 15 years post-huCART19-IL18 infusion
|
ALL Patients: Duration of time from the huCART19-IL18 infusion to the date of relapse/treatment failure, death or receipt of new anticancer therapy. |
Up to 15 years post-huCART19-IL18 infusion
|
|
Overall Survival (OS)
Délai: Up to 15 years post-huCART19-IL18 infusion
|
Duration of time from the huCART19-IL18 infusion to the date of death, for any reason |
Up to 15 years post-huCART19-IL18 infusion
|
|
Characterize low level disease and B cell assessment in response to huCART19-IL18 cells by Flow Cytometry
Délai: 12 months
|
Polychromatic flow cytometry-based assessment of leukemia and B cells, extent and duration of leukemic response |
12 months
|
|
Characterize low level disease and B cell assessment in response to huCART19-IL18 cells by Next Gen Sequencing
Délai: 12 months
|
Presence or absence of malignant B cells by Next-Generation Immunoglobulin heavy chain Sequencing (NGIS) |
12 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Jakub Svoboda, MD, University of Pennsylvania
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Tumeurs
- Maladie chronique
- Attributs de la maladie
- Maladies du système immunitaire
- Tumeurs par type histologique
- Maladies hématologiques
- Maladies lymphatiques
- Troubles lymphoprolifératifs
- Troubles immunoprolifératifs
- Leucémie, cellule B
- Lymphome
- Leucémie, Lymphoïde
- Leucémie
- Conditions pathologiques, signes et symptômes
- Maladies hémiques et lymphatiques
- Leucémie lymphocytaire chronique à cellules B
- Leucémie-lymphome lymphoblastique à cellules précurseurs
- Lymphome non hodgkinien
Autres numéros d'identification d'étude
- 15420; IRB# 844955
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .